Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1

Additional research demonstrates 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission "Standards of care for cardiometabolic health are evolving thanks to new GLP-1 medications, but research, including Dario's newest study, continues to demonstrate the importance of effective behavior change. These medications require the meaningful and sustainable change that Dario delivers for our members and our clients to support full realization of the value of these drugs," said Omar ...